|
|||||
|
|
Long‐term safety and efficacy of canagliflozin as add‐on therapy to teneligliptin in Japanese patients with type 2 diabetes |
|
| Authors: | Takashi Kadowaki MD PhD Nobuya Inagaki MD PhD Kazuoki Kondo MD PhD Kenichi Nishimura MS Genki Kaneko MS Nobuko Maruyama B. Pharm. Nobuhiro Nakanishi M. Math. Yumi Watanabe PhD Maki Gouda BSc. Hiroaki Iijima PhD |
| Affiliation: | 1. Department of Diabetes and Metabolic Diseases, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan;2. Department of Diabetes, Endocrinology, and Nutrition, Graduate School of Medicine, Kyoto University, Kyoto, Japan;3. Ikuyaku. Integrated Value Development Division, Mitsubishi Tanabe Pharma Corporation, Tokyo, Japan |
| Abstract: | |
| Keywords: | canagliflozin DPP‐4 inhibitor SGLT2 inhibitor teneligliptin type 2 diabetes mellitus |